News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vical Incorporated (VICL) Publication Highlights Milestone in Vaccine Development


10/3/2013 10:00:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the publication of a new article1 in a special DNA vaccine issue of the journal Vaccines detailing the development process from initial product concept to Phase 3 trial initiation for ASP0113 (TransVax™), Vical's investigational therapeutic vaccine designed to control cytomegalovirus (CMV) in transplant recipients. Vical and Astellas Pharma Inc. (TSE:4503) ("Astellas") entered into exclusive worldwide license agreements in 2011 to develop and commercialize ASP0113.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES